SUPN Earnings & Financial Statements
Supernus Pharmaceuticals, Inc.
$41.01
+$0.83(+2.07%)
53
Overall
60
Value
40
Tech
60
Quality
Market Cap
$2.44B
Volume
51.34K
52W Range
$40.51 - $59.68
Target Price
$61.75
SUPN earnings and financial statements: Supernus Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SUPN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M |
| Cost of revenue | $74.56M | $77.91M | $83.78M | $87.22M | $75.06M |
| Operating income | -$62.28M | $81.67M | -$5.27M | $46.12M | $86.03M |
| EBITDA | $50.51M | $183.74M | $90.58M | $150.94M | $146.69M |
| Net income | -$38.55M | $73.86M | $1.32M | $60.71M | $53.42M |
| EPS (diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.45B | $1.37B | $1.28B | $1.70B | $1.69B |
| Total liabilities | $390.93M | $332.34M | $356.16M | $816.30M | $873.30M |
| Shareholders’ equity | $1.06B | $1.04B | $921.52M | $886.20M | $815.85M |
| Cash and equivalents | $128.45M | $69.33M | $75.05M | $93.12M | $203.43M |
| Long-term debt | $30.36M | $27.38M | $33.20M | $36.00M | $420.55M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $47.33M | $171.95M | $111.08M | $116.83M | $127.13M |
| Capital expenditure | -$1.34M | -$725.0K | -$551.0K | -$412.0K | -$2.04M |
| Free cash flow | $45.99M | $171.23M | $110.53M | $116.41M | $125.08M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SUPN | $41.01 | +2.1% | 51.34K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Supernus Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW